Study strengthens concerns about long-term use of certain painkillers

(Medical Xpress) -- Painkillers such as ibuprofen, naxopren and celecoxib provide needed relief for many patients who have chronic pain. But an ongoing source of contention is whether those drugs and others in their class known as nonsteroidal anti-inflammatory drugs, or NSAIDs, are linked to harmful health effects.

Now a new study from the University of Florida raises the concern about potential risks to a higher degree than before, finding a doubling of deaths from heart attack, and related events among people who have both hypertension and and use the drugs long term.

The findings, based on data from the international INVEST clinical study of therapies, are published in the current issue of The .

“It does strengthen our practice recommendations,” said lead author Dr. Anthony A. Bavry, an assistant professor of cardiovascular medicine in the UF College of Medicine’s department of medicine.

Physicians already discourage the use of NSAIDs among the elderly and after heart attacks, on the basis of several studies showing that the drugs are linked with a higher risk of stroke and heart attack.

But the UF researchers, including senior author Dr. Carl J. Pepine, a professor of cardiovascular medicine in the UF College of Medicine, advise patients to talk to their doctors before stopping use of prescribed treatments.

“It’s a tricky issue, because NSAIDs are useful for relieving pain, and that is much of what we do in medicine — alleviate pain and suffering,” said Dr. Deepak L. Bhatt, an associate professor of medicine at Harvard Medical School and chief of cardiology at the VA Boston Healthcare System, who recently published findings that NSAIDs are linked to a higher risk of stroke. “Unfortunately, most medications have some potential side effects, and it’s important to know what those might be.” Bhatt was not involved in the UF study.

Patients who have both high blood pressure and coronary artery disease are generally put on aspirin, a unique type of NSAID, to reduce their risk of a heart attack. Physicians are concerned that giving those patients other NSAIDs for pain relief could cancel out aspirin’s beneficial effects and raise the risk of negative cardiovascular effects.

The UF research team took advantage of the availability of INVEST study data from 882 chronic NSAID users and almost 22,000 intermittent or nonusers to try to settle the question. They looked at patients who reported using NSAIDs over an average of about three years, to see whether there was an increase in adverse events or cardiovascular-related compared with patients who did not use those pain medicines long term.

The risk of death from cardiovascular causes was 2.3 times higher among patients who chronically used the drugs than among other patients.

NSAIDs are thought to act in a variety of ways to increase cardiovascular risk. They are thought to prevent aspirin’s protective anti-clotting effect by preventing the aspirin from binding properly to platelets in the blood. Some NSAIDs might also increase bleeding risk. In addition, NSAIDs raise blood pressure, thus potentially raising the risk of heart attack and stroke. Some NSAIDs have already been removed from the market because of concerns about an elevated risk of and stroke.

While randomized clinical trials are still needed to definitively show a link between NSAIDS and cardiovascular effects, the current study is only the latest in a growing body of research that strongly suggests an association.

“There have been enough studies now that it certainly raises suspicion,” Bhatt said. “The question that’s still open is, is it all NSAIDs, or are some worse than others?”

The UF study did not compare specific NSAIDs, so more research has to be carried out to determine the level of risk that might be associated with each.

The INVEST study was funded by Abbott Laboratories and the University of Florida Opportunity Fund. The National Institutes of Health also provided grant support for several of the researchers. Members of the research team have also received grant funding from, or served as consultants for, a number of pharmaceutical companies.

Related Stories

Ibuprofen puts high risk cardiac patients at risk

Apr 05, 2007

Doctors who treat the painful condition of osteoarthritis in patients with increased cardiovascular risk need to be cautious. A team lead by researchers at Mount Sinai School of Medicine, are the first to study outcomes in ...

Reducing side-effects of painkillers

Sep 12, 2006

Cardiff University researchers have increased the understanding of why some painkillers increase the risk of heart attack and stroke.

Recommended for you

Vaccine proves effective against deadly Middle East virus

Sep 15, 2014

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

Sep 15, 2014

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
not rated yet Jul 22, 2011
Disturbing research.

It raises the question, should aspirin continue to be prescribed/used to reduce the incidence of vascular events?

Is aspirin OK, or should it be avoided?

Hope there is further research to address this.
ziphead
not rated yet Jul 26, 2011
Disturbing research.

It raises the question, should aspirin continue to be prescribed/used to reduce the incidence of vascular events?

Is aspirin OK, or should it be avoided?

Hope there is further research to address this.


Breath in. Then out.
1. This is a long known issue with COX-2 selective NSAIDs.
2. Aspirin is not one of those.
3. And don't worry, there will be way more research about this, only not the kind that looks at natural alternatives. Like boswellic acid, for instance.
dogbert
not rated yet Jul 26, 2011
The study was not about the COX-2 selective NSAIDs. It was about NSAIDs in general.

I think that only one COX-2 selective NSAID remains available and it has little use.